Percutaneous absorption of interferon-α by self-dissolving micropiles

References

• Barry B, Williams A. Penetration enhancers. Adv Drug Deliv Rev 2003; 56: 603–618
   Web of Science ®Google Scholar
• Borden EC, Hogan TF, Voelkal JG. The comparative antiproliferative activity in vitro of natural interferons for diploid and transformed human cells. Cancer Res 1982; 42: 4948–4953
   PubMed Web of Science ®Google Scholar
• Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004; 56: 675–711
   PubMed Web of Science ®Google Scholar
• Chandrasekaran S, Brazzle JD, Frazier AB. Surface micromachined metallic microneedles. J Microelectromech Syst 2003; 12: 281–288
   Web of Science ®Google Scholar
• Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1493–1499
   PubMed Web of Science ®Google Scholar
• Eyles JE, Alpar HO, Conway BR, Keswick M. Oral delivery and fate of poly (lactic acid) microsphere-encapsulated interferon in rats. J Pharm Pharmacol 1997; 49: 669–674
   PubMed Web of Science ®Google Scholar
• García-Compean D, Blanc P, Larrey D, Daures JP, Hirtz J, Mendoza E, Maldonado H, Michel H. Treatment of cirrhotic tense ascites with Dextran-40 versus albumin associated with large volume paracentesis: A randomized controlled trial. Ann Hepatol 2002; 1: 29–35
   PubMedGoogle Scholar
• Gresser I, Maury C, Brouty-Boye D. Mechanism of the antitumor effects of interferon in mice. Nature 1972; 239: 167–168
   PubMed Web of Science ®Google Scholar
• Gresser I, Maeyer-Guignard JD, Tovey MG, Maeyer ED. Electrophoretically pure mouse interferon exerts multiple biologic effects. Proc Natl Acad Sci USA 1979; 76: 5308–5312
   PubMed Web of Science ®Google Scholar
• Griss P, Enoksson P, Stemme G. Micromachined barbed spikes for mechanical chip attachment. Sens Acutuators A Phys 2002; 95: 94–99
   Web of Science ®Google Scholar
• Hizawa N, Kojima J, Kojima T, Sukoh N, Yamaguchi E, Kawakami Y, Matsushima T. A patient with chronic hepatitis C who simultaneously developed interstitial pneumonia, hemolytic anemia and cholestatic liver dysfunction after alpha-interferon administration. Intern Med 1994; 33: 337–341
   PubMed Web of Science ®Google Scholar
• Hwang SJ. Hepatitis C virus infection: An overview. J Microbiol Immunol Infect 2001; 34: 227–234
   PubMedGoogle Scholar
• Ito Y, Tosh B, Togashi Y, Amagase K, Kishida T, Sugioka N, Shibata N, Takada K. Absorption of interferon alpha from patches in rats. J Drug Target 2005; 13: 383–390
   PubMed Web of Science ®Google Scholar
• Ito Y, Yoshimitsu JI, Shiroyama K, Sugioka N, Takada K. Self-dissolving microneedles fir the percutaneous absorption of EPO in mice. J Drug Target 2006a; 14: 255–262
   PubMed Web of Science ®Google Scholar
• Ito Y, Hagiwara E, Saeki A, Sugioka N, Takada N. Feasibility of microneedles for percutaneous absorption of insulin. Eur J Pharm Sci 2006b; 29: 82–88
   PubMed Web of Science ®Google Scholar
• Kanno A, Yamada M, Abe M, Okamoto Y. A case of interferon alpha-induced manic psychosis in chronic hepatitis C. Tohoku J Exp Med 1999; 187: 79–82
   PubMed Web of Science ®Google Scholar
• Kim K, Park DS, Lu HM, Che W, Kim K, Lee JB, Ahn CH. A tapered hollow metallic microneedle array using backside exposure of SU-8. J Micromech Microeng 2004; 14: 597–603
   Web of Science ®Google Scholar
• Knight E, Jr. The molecular structure of interferons. Interferon: General and applied aspects, A Billiau. Elsevier Science Publishers, Amsterdam 1984; 61–78
   Google Scholar
• Leventhal BG. Treatment of virus-associated tumors with interferon. The interferon system, S Baron, F Dianzani, GJ Stanton, WR Fleischmann, Jr. University of Texas Press, Austin 1987; 477–486
   Google Scholar
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: l485–l492
   Google Scholar
• Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkerhagel RM, Aguet M. Functional role of type I and type II interferons in antiviral defense. Science 1994; 264: 1918–1921
   PubMed Web of Science ®Google Scholar
• Nagano Y, Kojima Y. Immunizing property of vaccinia virus inactivated by ultraviolets rays. C R Seances Soc Biol Fil 1954; 148: 1700–1702
   PubMedGoogle Scholar
• Ollero M, Cebrian-Perez JA, Muiño-Blanco T. Improvement of cryopreserved ram sperm heterogeneity and viability by addition of seminal plasma. J Androl 1997; 18: 732–739
   PubMed Web of Science ®Google Scholar
• Patel K, McHutcison J. Peginterferon alpha-2b: A new approach to improving response in hepatitis C patients. Expert Opin Pharmacother 2001; 2: 1307–1315
   PubMedGoogle Scholar
• Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426–1432
   PubMed Web of Science ®Google Scholar
• Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004; 56: 581–587
   PubMed Web of Science ®Google Scholar
• Quesada JR, Talpaz MR. Clinical toxicity of interferon in cancer patients: A review. J Clin Oncol 1986; 4: 234–243
   PubMed Web of Science ®Google Scholar
• Radwanski E, Perentesis G, Jacobs S, Oden E, Affrime M, Symchowicz S, Zampaglione N. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 1987; 27: 432–435
   PubMed Web of Science ®Google Scholar
• Ruiz L, Reyes N, Aroche K, Tolosa V, Simanca V, Rodriguez T, Hardy E. Influence of packaging material on the liquid stability of interferon α-2b. J Pharm Pharm Sci 2005; 8: 207–216
   PubMed Web of Science ®Google Scholar
• Shibata N, Ito Y, Takada K. Handbook of pharmaceutical biotechnology, Cox Gad Shayne. Wiley-Interscience, NY 2007; 757–814, Chapter 6.3. Pharmacokinetics
   Google Scholar
• Supersaxo A, Hein WR, Steffen H. Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 1990; 7: 167–169
   PubMed Web of Science ®Google Scholar
• Takada K. Oral delivery of haematopoietic factors: Progress with gastrointestinal mucoadhesive patches, microdevices and other microfabrication technologies. Am J Drug Deliv 2006; 4: 65–77
   Google Scholar
• Yamazaki S. Further studies on clinical trials of interferon in Japan. Jpn J Med Sci Biol 1984; 37: 209–223
   PubMedGoogle Scholar
• Yoshikawa Y, Kato K, Sone H, Takada K. Development and evaluation of noncompartmental pharmacokinetic analysis program WinHARMONY using Visual BASIC language having a function of an automatic recognition of terminal elimination phase of plasma drug concentration vs. time profile. Jpn J Clin Pharm Ther 1998; 29: 475–487
   Google Scholar